- Motley Fool•4 hours ago
This dynamic duo appears to be on track to give Gilead's portfolio of hepatitis C products a run for its money.
- Reuters•4 hours ago
German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab. Johnson & Johnson said earlier the experimental biotech drug proved more effective at clearing moderate to severe cases of the skin condition than a placebo or Abbvie's Humira, the world's top-selling prescription medicine. A Morphosys spokesman said on Saturday that guselkumab could now become its first drug to market, depending on whether and when Johnson & Johnson makes an application.
Johnson & Johnson (JNJ)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||117.85 x 400|
|Ask||118.29 x 500|
|Day's Range||117.39 - 118.62|
|52wk Range||92.58 - 126.07|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||22.01|
|Avg Vol (3m)||6,259,060|
|Dividend & Yield||3.20 (2.73%)|